BERLIN (Reuters) – The Swiss drugmaker said on Thursday that Novartis is the subject of an investigation by the Swiss Competition Commission into the use of patents.
“Novartis is cooperating fully with the authorities and is confident that the legality of its position has been clarified,” she said in a statement, adding that the opening of an investigation did not indicate any wrongdoing or financial implications.
She added that Novartis would not comment further on the investigation at this time.
